- Home
- BRTX
as 07-26-2024 4:00pm EST
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MELVILLE |
| Market Cap: | 11.8M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 68.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $3.67 | Next Earning Date: | 08-09-2024 |
| Revenue: | $149,500 | Revenue Growth: | 10.66% |
| Revenue Growth (this year): | 293.52% | Revenue Growth (next year): | 110.72% |
Stock Insider Trading Activity of BioRestorative Therapies Inc. (NV) (BRTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Silva Francisco | BRTX | VP of Research and Development | Apr 8 '24 | Buy | $1.13 | 476 | $537.88 | 147,927 | SEC Form 4 |
| Silva Francisco | BRTX | VP of Research and Development | Apr 8 '24 | Buy | $1.17 | 1,232 | $1,441.44 | 149,159 | SEC Form 4 |
| Silva Francisco | BRTX | VP of Research and Development | Apr 8 '24 | Buy | $1.25 | 6,600 | $8,250.00 | 155,759 | SEC Form 4 |
| Broadrick Dale | BRTX | 10% Owner | Feb 8 '24 | Buy | $1.25 | 73,959 | $92,448.75 | 391,931 | SEC Form 4 |
| Broadrick Dale | BRTX | 10% Owner | Feb 8 '24 | Buy | $1.32 | 86,041 | $113,574.12 | 477,972 | SEC Form 4 |
| Broadrick Dale | BRTX | 10% Owner | Feb 7 '24 | Buy | $1.38 | 36,374 | $50,196.12 | 363,419 | SEC Form 4 |
| Broadrick Dale | BRTX | 10% Owner | Feb 7 '24 | Buy | $1.34 | 83,626 | $112,058.84 | 447,045 | SEC Form 4 |
| Broadrick Dale | BRTX | 10% Owner | Dec 1 '23 | Sell | $1.88 | 250 | $469.25 | 327,045 | SEC Form 4 |
| Broadrick Dale | BRTX | 10% Owner | Nov 27 '23 | Sell | $1.89 | 278 | $525.42 | 327,295 | SEC Form 4 |
Latest BioRestorative Therapies Inc. (NV) News
BRTX Breaking Stock News: Dive into BRTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
GlobeNewswire
a month ago
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
GlobeNewswire
a month ago
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
MT Newswires
a month ago
Top Midday Gainers
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
BioRestorative Therapies in Licensing Talks for Metabolic Disease Program -- Shares Rise Pre-Bell
GlobeNewswire
a month ago
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
Compare BRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BRTX BioRestorative Therapies Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.